Literature DB >> 28508359

Evolving Relevance of Neuroproteomics in Alzheimer's Disease.

Simone Lista1,2, Henrik Zetterberg3,4, Sid E O'Bryant5, Kaj Blennow3,6, Harald Hampel7,8.   

Abstract

Substantial progress in the understanding of the biology of Alzheimer's disease (AD) has been achieved over the past decades. The early detection and diagnosis of AD and other age-related neurodegenerative diseases, however, remain a challenging scientific frontier. Therefore, the comprehensive discovery (relating to all individual, converging or diverging biochemical disease mechanisms), development, validation, and qualification of standardized biological markers with diagnostic and prognostic functions with a precise performance profile regarding specificity, sensitivity, and positive and negative predictive value are warranted.Methodological innovations in the area of exploratory high-throughput technologies, such as sequencing, microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation of large global molecular datasets from a multiplicity of biological systems, such as biological fluids, cells, tissues, and organs. Such methodological progress has shifted the attention to the execution of hypothesis-independent comprehensive exploratory analyses (opposed to the classical hypothesis-driven candidate approach), with the aim of fully understanding the biological systems in physiology and disease as a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous computational modelling to describe and foresee the dynamic features of biological systems. The use of dynamically evolving technological platforms, including mass spectrometry, in the area of proteomics has enabled to rush the process of biomarker discovery and validation for refining significantly the diagnosis of AD. Currently, proteomics-which is part of the systems biology paradigm-is designated as one of the dominant matured sciences needed for the effective exploratory discovery of prospective biomarker candidates expected to play an effective role in aiding the early detection, diagnosis, prognosis, and therapy development in AD.

Entities:  

Keywords:  Alzheimer’s disease; Biomarkers; Blood; Cerebrospinal fluid; Detection/diagnosis; Mass spectrometry; Neuroproteomics; Omics sciences; Plasma/serum; Proteomics; Systems biology

Mesh:

Substances:

Year:  2017        PMID: 28508359     DOI: 10.1007/978-1-4939-6952-4_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.

Authors:  Lenora Higginbotham; Lingyan Ping; Eric B Dammer; Duc M Duong; Maotian Zhou; Marla Gearing; Cheyenne Hurst; Jonathan D Glass; Stewart A Factor; Erik C B Johnson; Ihab Hajjar; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Sci Adv       Date:  2020-10-21       Impact factor: 14.136

Review 2.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Authors:  Harald Hampel; Sid E O'Bryant; José L Molinuevo; Henrik Zetterberg; Colin L Masters; Simone Lista; Steven J Kiddle; Richard Batrla; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

Review 3.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.